https://gdc-0980inhibitor.com/....cs3-pb2-ch3-coo2-x5-
There clearly was no difference in blood loss (2020.2 vs 1914.1 mL, = .437) between groups. Total problems (37.0% vs 33.2%, = .05 complications were similar between groups. TXA wasn't independently associated with loss of blood or TXA-related complications. Both teams had similar intensive treatment device (2.5 versus 2.0 times, = .19 remains. There were no differences in outcomes between TXA dosing subgroups. Systemic TXA use during 3CO for ASD surgery had not be
Like
Comment
Share
